	Nonvertebral fractures
Hip fractures
Epidemiology
Bisphosphonates
Osteoporosis
	hip fractures
multiple health plans
once-a-week
clinical practice
patients
baseline characteristics
consistent
date
alendronate
nonvertebral fractures
hip
therapy
bisphosphonate use
differences
months
primary analysis
risk factors
study
data
results
health plan
days
randomized clinical trials
fractures
fracture reduction
mg daily
clinical
lower
risedronate
trials
Conclusion Patients
characteristics
sensitivity analysis
incidence
bisphosphonates
Results There
effect
methods
end
cohort
models

